Orexin A, human

Orexin A, human is a neuropeptide belonging to the orexin/hypocretin family, characterized by its pivotal role in regulating arousal, energy homeostasis, and neuroendocrine functions within the central nervous system. Synthesized as part of a prepro-orexin precursor, Orexin A is predominantly expressed in the lateral hypothalamus and is well-recognized for its involvement in modulating wakefulness, appetite, and reward pathways. The human form of Orexin A, comprising a highly conserved amino acid sequence, serves as a critical molecular tool for elucidating the physiological and pathophysiological mechanisms underlying sleep-wake regulation, feeding behavior, and neuropsychiatric disorders. Its unique receptor specificity and pharmacological profile render it invaluable for both fundamental neuroscience research and translational studies targeting orexinergic signaling pathways.

Neuroscience research: Orexin A is extensively employed in experimental studies investigating the neurobiological basis of sleep-wake cycles, arousal, and vigilance. By applying the peptide in in vitro and in vivo models, researchers can dissect the orexinergic modulation of neuronal activity, synaptic transmission, and network oscillations within key brain regions such as the hypothalamus, locus coeruleus, and cortex. These studies provide critical insights into the molecular and circuit-level mechanisms that govern behavioral state transitions and the maintenance of alertness.

Metabolic regulation studies: The peptide serves as an essential tool for probing the complex interplay between central orexin signaling and peripheral metabolic processes. Orexin A has been shown to influence feeding behavior, energy expenditure, and glucose homeostasis, making it highly relevant for metabolic research. Experimental administration of the peptide enables the exploration of its effects on appetite control, thermogenesis, and lipid metabolism, thereby advancing the understanding of neuroendocrine regulation in obesity, diabetes, and related metabolic disorders.

Pharmacological screening: Due to its defined receptor selectivity for orexin receptors OX1R and OX2R, Orexin A is utilized in high-throughput screening assays and ligand-binding studies aimed at characterizing receptor pharmacodynamics and identifying novel modulators of the orexin system. This application is particularly valuable for the development of small-molecule agonists, antagonists, or allosteric modulators, supporting drug discovery programs focused on neuropsychiatric and sleep-related indications.

Behavioral neuroscience: The functional peptide is frequently applied in behavioral paradigms to assess its impact on motivation, reward processing, and stress responsiveness. By administering Orexin A in animal models, investigators can evaluate alterations in locomotor activity, operant conditioning, and anxiety-like behaviors, thereby elucidating the broader role of the orexinergic system in emotional and cognitive regulation.

Electrophysiological investigations: Orexin A provides a precise means to study its direct and indirect effects on neuronal excitability and synaptic plasticity. Patch-clamp recordings and other electrophysiological techniques utilize the peptide to characterize orexin receptor-mediated currents, second messenger pathways, and modulation of neurotransmitter release. These approaches are instrumental in mapping the cellular and molecular underpinnings of orexinergic signaling in both normal and diseased states.

1. Odorant binding protein based biomimetic sensors for detection of alcohols associated with Salmonella contamination in packaged beef

2. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes

3. Relatedness of antibodies to peptides containing homocitrulline or citrulline in patients with rheumatoid arthritis

4. Proinsulin C-peptide and insulin: Limited pattern similarities of interest in inter-peptide interactions but no C-peptide effect on insulin and IGF-1 receptor signaling

5. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry